IRDiRC-Related Calls

IRDiRC does not provide centralized grants. Its members have a number of funding opportunities available in the field of rare disease research that are in compliance with IRDiRC rules and guidelines. These funding opportunities are listed below.

 

April 2017

New therapies for rare diseases – SC1-PM-08-2017 (Horizon 2020, EU)

EUflag_yellow50x34px
Support will be provided to clinical trials on substances where orphan designation has been given by the EC, where the proposed clinical trial design takes into account recommendations from protocol assistance given by the EMA (European Medicines Agency), and where a clear patient recruitment strategy is presented.

Expected Impact:
In line with the objectives of the EU pharmaceutical legislation on orphan medicinal products, proposals shall contribute to advance the development of new therapeutic options with concrete benefits for patients
living with rare diseases.
• Rapid progress in orphan drug development due to well-prepared clinical trials and a multinational multi-centre clinical trial with an appropriate number of patients
• Develop a preliminary assessment of the potential economic and public health aspects of the new therapeutic option
• Contribute to growth of SMEs involved in drug development
• In line with the Union’s strategy for international cooperation in research and innovation, proposals shall contribute towards IRDiRC objectives.

Full details of the call

DEADLINES: April 11, 2017

PhD Proposals – AFM Téléthon

This International Call for Proposals, open to both French and foreign groups, aims to support research which will:

    1. Increase our understanding of the neuromuscular system
    2. Encourage the development of therapies for neuromuscular diseases and rare genetic diseases

Full details of the call 

DEADLINES: April 25, 2017

Human and Social Sciences & Rare Diseases – French Foundation for Rare Diseases

The French Foundation for Rare Diseases launches a fifth call for projects “Social and Human Sciences & rare diseases” in collaboration with the Caisse Nationale de Solidarité and the IRCEM Corporate Foundation. This call for proposals is intended to get a better understanding of individual consequences, family and social specifically related to the scarcity of the disease and increase knowledge on the specific impact of these diseases in terms of disability and of quality of life (activity limitations, restriction of social participation, human rights).

Full details of the call (in French)

DEADLINES: April 27, 2017

June 2017

E-Rare-3 Joint Transnational Call (2017) (CIHR, Canada)

There are at least 6000 to 7000 distinct rare diseases, the great majority being of genetic origin. Although individually rare, taken together rare diseases affect at least 26-30 million people in Europe alone. Moreover, they represent a major issue in health care: a large number of these diseases lead to a significant decrease of life expectancy and most of them cause chronic illnesses with a large impact on quality of life and the health care system.

Therefore, research on rare diseases is needed to provide knowledge for prevention, diagnosis and better care of patients. Yet, research is hampered by lack of resources at several levels:

  1. Few scientists work on one specific disease;
  2. There are few patients per disease and they are scattered over a large geographic area, causing difficulties gathering the necessary cohorts;
  3. Existing databases and material collections are usually local, small, and not accessible or standardized; and
  4. Diseases often have complex clinical phenotypes and require interdisciplinary cooperation for research, hence, interdisciplinary approaches to treatment.

In this context, the ERA-NET “E-Rare” for research programs on rare diseases has been extended to a third phase “E-Rare-3” (2014-2019) to further help in coordinating the research efforts of participating countries in the field of rare diseases and implement the objectives of the International Rare Disease Research Consortium (IRDiRC). CIHR is pleased to be partnering with Muscular Dystrophy Canada (MDC) and the Fonds de recherche du Québec – Santé (FRQS) once again in the context of this ERA-Net.

 

The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear translational research approach.

Project shall involve: a group of rare diseases or a single rare disease following the European definition i.e. disease affecting not more than five in 10,000 persons in the European Community, EC associated states and Canada.

Full details of the call

DEADLINE: June 6, 2017

Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases – R42 (NIH, USA)

USA
This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose preclinical studies to advance the development of biomarkers or treatments for rare musculoskeletal, rheumatic or skin diseases.  Rare diseases have a prevalence of fewer than 200,000 affected individuals in the United States.  Also eligible for potential funding through this initiative are studies of FDA-designated orphan products for musculoskeletal, rheumatic or skin diseases.

Full details of the call

DEADLINE: June 10, 2017

Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers – R21 (NIH, USA)

USA
This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

Full details of the call

DEADLINES: June 16, 2017; October 16, 2017

Research Grants for Rare Diseases and Their Family Caregivers – (NORD, USA)

USA

NORD’s research grant funding for the 2017 cycle is available for study of:

  • Alveolar Capillary Dysplasia with Misalignment of the Pulmonary Veins – One (1) grant of up to $50,000, for scientific and/or clinical research studies related to Alveolar Capillary Dysplasia with Misalignment of the Pulmonary Veins (ACD/MPV). See full RFP and abstract proposal template here.
  • Appendix Cancer and Pseudomyxoma Peritonei – Three (3) grants of up to $50,000 for scientific and/or clinical research studies related to Appendix Cancer and/or Pseudomyxoma Peritonei (PMP). See full RFP and abstract template here.
  • Cat Eye Syndrome – One (1) grant of up to $30,000 for scientific and/or clinical research studies related to Cat Eye Syndrome. See full RFP and abstract template here.
  • Malonic Aciduria – One (1) grant of up to $50,000 for scientific and/or clinical research studies related to Malonic Aciduria. See full RFP and abstract template here.
  • Post-Orgasmic Illness Syndrome – One (1) grant of up to $31,000 for scientific and/or clinical research studies related to Post-Orgasmic Illness Syndrome (POIS). See full RFP and abstract template here.

Grants are made possible by donations to NORD.  In some cases, the grants are co-sponsored by NORD and disease-specific patient organizations.

Full details of the call

DEADLINES: June 23, 2017

July 2017

Research Grants – AFM Téléthon

This International Call for Proposals, open to both French and foreign groups, aims to support research which will:

    1. Increase our understanding of the neuromuscular system
    2. Encourage the development of therapies for neuromuscular diseases and rare genetic diseases

Full details of the call

DEADLINES: July 4, 2017

Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers – R01 (NIH, USA)

USA
This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

Research projects submitted to this FOA should focus on palliative and end-of-life care for individuals with advanced, rare diseases and their family caregivers. Studies may consider changing needs that occur across time points and disease progression, as well as ways in which EOLPC and planning can adapt to meet these changing needs. Childhood cancers are not of interest for the purposes of this FOA.

Research projects of interest include, but are not limited to those that:

  • Determine the unique EOLPC needs and preferences (including decision-making) of individuals with advanced, rare diseases and their family caregivers.
  • Contribute seminal data on how needs and preferences of individuals with rare diseases and their family caregivers change across stages of an illness, to provide evidence for future intervention-based studies.
  • Design, test, evaluate, and/or compare EOLPC interventions or models of care to support individuals living with advanced, rare diseases.
  • Design, test, and evaluate, and/or compare EOLPC interventions or models of care to support family caregivers of those living with advanced, rare diseases.
  • To establish key indicators of and appropriate measurements for quality outcomes in individuals with advanced, rare diseases and their family caregivers.
  • Identify transition points at the advanced stages of illness which result in a change in palliative or hospice care needs and develop evidence-based interventions/models of care support during these critical transition points.
  • Foster new research to determine the readiness of individuals with advanced, rare diseases and their families to engage in integrated palliative care.
  • Develop and test innovative technologies for use in palliative and/or hospice care models for individuals with rare diseases.

Full details of the call

DEADLINES: July 5, November 5, 2017

August 2017

NeuroNEXT Clinical Trials -U01 (NIH, USA)

USA
This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS’ strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Applicants do not need to be part of the existing NeuroNEXT infrastructure.

Full details of the call

DEADLINES: August 3, 2017

Natural History Studies for Rare Disease Product Development: Orphan Products Research Project Grant -R01 (FDA, USA)

USA
The objective of FDA’s Orphan Products Natural History Grants Program is to support studies that advance rare disease medical product development through characterization of the natural history of rare diseases/conditions, identification of genotypic and phenotypic subpopulations, and development and/or validation of clinical outcome measures, biomarkers and/or companion diagnostics. The ultimate goal of these natural history studies is to support clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA provides grants for natural history studies that will either assist or substantially contribute to market approval of these products. Applicants must include in the application’s Background and Significance section documentation to support that the estimated prevalence of the orphan disease or condition in the United States (US) is less than 200,000 (or in the case of a vaccine or diagnostic, information to support that the product will be administered to fewer than 200,000 people in the US per year), and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.  Additional information may be required upon request, for example, regarding population estimate and rationale.

Full details of the call

DEADLINES: August 31, 2017

February 2018

Clinical studies of safety and effectiveness of orphan products research project grant (FDA, USA)

USA
The goal of FDA’s OOPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product being developed will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. Applicants must include in the application’s Background and Significance section documentation to support the assertion that the orphan disease or condition to be studied is a “rare disease or condition” and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.

The grants are available to any foreign or domestic, public or private, for-profit or nonprofit entity (including State and local units of government). Federal agencies that are not part of the Department of Health and Human Services (HHS) may apply. Agencies that are part of HHS may not apply.  For-profit entities must commit to excluding fees or profit in their request for support to receive grant awards. Organizations that engage in lobbying activities are not eligible to receive grant awards.

Full details of the call

DEADLINES: February 7, 2018 

No deadline – applications on an ongoing basis

Canadian “Rare Diseases: Models & Mechanisms” Network (RDMM, Canada)

Canada
On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system.

Three categories of Connection applications will be considered:

  1. Novel gene supported by genetic evidence (mutations in the same gene in unrelated patients with a similar phenotype) and functional data is being rapidly sought prior to publication.
  2. Candidate gene for a rare disease in a single patient/family/isolated population such that additional functional data is necessary to support disease-causation.
  3. Known disease gene that is of therapeutic or biological interest to a unique Canadian population or community (e.g. Hutterite, First Nation, French Canadian, patient advocacy group etc.).

Funds Available:
A maximum of $25,000 will be awarded for each catalyst grant.

Eligibility:
Applications may be submitted by any investigator associated with a Canadian Institution.

Full details of the call